Key points from article :
Selected UBX1967 as new lead drug to treat age-related diseases of the eye.
Turns off signalling proteins that encourage cells to not activate programmed cell suicide (apoptosis).
The drug may be effective among age-related diseases not involving the eyes.
Animal toxicity testing to start in second half of 2019.
